<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04140448</url>
  </required_header>
  <id_info>
    <org_study_id>UWFA-RVO-ME</org_study_id>
    <nct_id>NCT04140448</nct_id>
  </id_info>
  <brief_title>Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion</brief_title>
  <acronym>UWFA-RVO-ME</acronym>
  <official_title>Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Renmin Hospital of Wuhan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study mainly observed the ischemic index and vascular leakage index changes on
      ultra-wide field fluorescence angiography after anti-VEGF treatment , and whether these
      changes correlated with treatment efficacy in patients with macular edema secondary to
      retinal vein occlusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ultra-wide field fluorescence angiography can clearly observe the peripheral retina. This
      study mainly observes the ischemic index and vascular leakage index changes on UWFA after
      anti-VEGF treatment and evaluates these changes associated with treatment efficacy in
      patients with macular edema secondary to retinal vein occlusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in vascular leakage index in different retinal area</measure>
    <time_frame>Baseline and 1,2,3,4,6,9 and 12 months</time_frame>
    <description>Change in vascular leakage index in different retinal area from baseline to 1,2,3,4,6,9 and 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in non-perfused areas in different retinal area</measure>
    <time_frame>Baseline and 1,2,3,4,6,9 and 12 months</time_frame>
    <description>Change in non-perfused areas in different retinal area from baseline to 1,2,3,4,6,9 and 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity</measure>
    <time_frame>Baseline and 1,2,3,4,6,9 and 12 months</time_frame>
    <description>Change in best corrected visual acuity from baseline to 1,2,3,4,6,9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in central macular thickness</measure>
    <time_frame>Baseline and 1,2,3,4,6,9 and 12 months</time_frame>
    <description>Change in central macular thickness from baseline to1,2,3,4,6,9 and12 months</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>UWFA-RVO-ME</arm_group_label>
    <description>Ultra-wide-field fundus fluorescein angiography on patients with macular edema secondary to retinal vein occlusion treated with Ranibizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]</intervention_name>
    <description>Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML</description>
    <arm_group_label>UWFA-RVO-ME</arm_group_label>
    <other_name>Lucentis</other_name>
    <other_name>Anti-VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultra-wide Fluorescein Angiography</intervention_name>
    <description>Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina</description>
    <arm_group_label>UWFA-RVO-ME</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged 18 years or older

          2. Macular edema secondary to CRVO,BRVO or HRVO

          3. Duration of RVO not more than 4 months

          4. Na√Øve patients. Patient with previous RVO (more than 12 months before the inclusion
             date) completely resolved (normalization of visual acuity and fundus examination) and
             who have experienced a recurrence of RVO are also considered naive

          5. Patient who agrees to participate in the study and who has given his/her written,
             informed consent

        Exclusion Criteria:

          1. Patient with another retinal disease in the study eye: diabetic retinopathy,
             maculopathy of any cause (age-related macular degeneration, epimacular membrane,
             myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely
             affecting vision and/or requiring surgical treatment during the 24 months study period

          2. Active or suspected ocular or periocular infection

          3. Active severe intraocular inflammation

          4. RVO complicated with neovascularization

          5. Patient who has previously undergone laser panretinal photocoagulation, grid-laser or
             photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study
             eye

          6. Patient already included in the study for the treatment of the fellow eye

          7. Pregnant or breastfeeding woman

          8. Lack of effective contraception for women of childbearing age

          9. Patient taking part in an interventional study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CZ Chen, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renmin Hospital of Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CZ Chen, PHD</last_name>
    <phone>+86 13072765173</phone>
    <email>whuchenchzh@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CZ Chen, PHD</last_name>
      <phone>+86 13072765173</phone>
      <email>whuchenchzh@163.com</email>
    </contact>
    <contact_backup>
      <last_name>XL Wang</last_name>
      <phone>+86 13117192316</phone>
      <email>wangxl0807@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 24, 2019</study_first_submitted>
  <study_first_submitted_qc>October 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>October 28, 2019</last_update_submitted>
  <last_update_submitted_qc>October 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Renmin Hospital of Wuhan University</investigator_affiliation>
    <investigator_full_name>Changzheng Chen</investigator_full_name>
    <investigator_title>Chief of Department of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Ultra-wide field fundus fluorescein angiography</keyword>
  <keyword>ischemic index</keyword>
  <keyword>vascular leakage index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

